Sign in

Roberta Turiello

@rturiello.bsky.social
56 followers 114 following 15 posts

🥼 Post-doctoral Researcher at the Telethon Institute of Genetics and Medicine, NA🇮🇹 Previously Postdoc at IEO, UKB, Bonn 🇩🇪 🔬Genomic and Experimental Medicine |Rare cancers | Rare genetic diseases 🛸 Spatial Biology enthusiast 📚 Bookworm 🇮🇹 Padula, SA

PostsRepliesMedia
Roberta Turiello @rturiello.bsky.social · 23/06/2026
🌌What happens to neutrophils during adoptive cell therapy? Find it out in this new paper from my brilliant colleagues, who mapped the spatiotemporal dynamics of neutrophils during ACT and uncovered distinct patterns actoss lymph nodes. #spatialbiology #celltherapy www.nature.com/articles/s41...
nature.com
Longitudinal spatial neutrophil profiling during ACT in murine melanoma reveals distinct lymph node infiltration patterns - npj Systems Biology and Applications
npj Systems Biology and Applications - Longitudinal spatial neutrophil profiling during ACT in murine melanoma reveals distinct lymph node infiltration patterns
000
Roberta Turiello @rturiello.bsky.social · 16/06/2026
☄️ To all the spatial biology enthusiasts out there! #spatialbiology www.biorxiv.org/content/10.6...
biorxiv.org
SPARQ-MI leverages end-to-end spatial single-cell analysis of the tumor microenvironment
Detailed spatial analysis of the tumor micro-environment (TME) through multiplexed fluorescence imaging requires quantitative image-processing and data-analysis methods. While data-preprocessing down ...
000
Roberta Turiello @rturiello.bsky.social · 12/04/2026
Tumor revascularization in #glioblatoma is driven by 2 spatially distinct pathways. The GLORIA trial investigated a novel first-line approach for #glioblastoma patients with unfavorable prognostic features: #radiotherapy + #LRNAaptamer targeting #CXCL12 + #bevacizumab www.nature.com/articles/s41...
nature.com
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial - Nature Communications
Recently, the dose escalation stage of the GLORIA trial investigating NOX-A12 (L-RNA aptamer-based CXCL12 inhibitor) in combination with radiotherapy in patients with glioblastoma was reported. Here, ...
100
Reposted by Roberta Turiello
Waggoner Lab @labwaggoner.bsky.social · 26/02/2026
@biorxivpreprint.bsky.social Longitudinal spatial profiling of neutrophils during adoptive T cell therapy in murine melanoma reveals distinct lymph node infiltration patterns across anatomical sites www.biorxiv.org/content/10.6...
041
Roberta Turiello @rturiello.bsky.social · 24/06/2025
🚨 New Paper in European Journal of Immunology! We show that NKG7 is a robust marker of cytotoxicity, outperforming GZMB and PRF1 across immune cell types and tissues! Thanks to all co-authors, @nsssusanna.bsky.social, @M.Hoelzel & @eomesodermin.bsky.social 📖 onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com
NKG7 is a Stable Marker of Cytotoxicity Across Immune Contexts and Within the Tumor Microenvironment
Cytotoxicity-associated genes exhibit heterogeneity at the cellular and tissue levels (left). NKG7 gene expression is strongly associated with a cytotoxic gene signature (middle). NKG7 expression is ...
744
Reposted by Roberta Turiello
Waggoner Lab @labwaggoner.bsky.social · 09/02/2025
NKG7 is a stable marker of cytotoxicity across immune contexts and within the tumor microenvironment www.biorxiv.org/content/10.1... @eomesodermin.bsky.social @nsssusanna.bsky.social @rturiello.bsky.social
065
Roberta Turiello @rturiello.bsky.social · 12/12/2024
The inaugural conference of the European Society for Spatial Biology (#ESSB) has kicked off today in Berlin! #IEO is here and represented by me and our PhD students Tim and Lukas. Come say hi, we got cool stories to share! 🟤 Interested in melanoma? Find me at poster #171 or shoot me a message!
130
Roberta Turiello @rturiello.bsky.social · 08/12/2024
The #MelanomaBridge was the first conference I attended, after starting my PhD in 2018. This year, I had the privilege of returning as a postdoc, showing some of my data. 3 days of inspiring talks and thought-provoking debates. Heading back to Bonn now, with new ideas and inspiration for my project
040